An emerging direction in glucagon-based therapy

Coskun, 2022, LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept, Cell Metab., 34, 1234, 10.1016/j.cmet.2022.07.013 Muller, 2017, The new biology and pharmacology of glucagon, Physiol. Rev., 97, 721, 10.1152/physrev.00025.2016 Nahra, 2021, Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study, Diabetes Care, 44, 1433, 10.2337/dc20-2151 Patil, 2020, Glucagon-based therapy: past, present and future, Peptides, 127, 10.1016/j.peptides.2020.170296 Sekar, 2022, Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes, Cell Metab., 34, 1824, 10.1016/j.cmet.2022.09.022 Sutkeviciute, 2020, Structural insights into emergent signaling modes of G protein-coupled receptors, J. Biol. Chem., 295, 11626, 10.1074/jbc.REV120.009348